Mira Pharmaceuticals, Inc. SEC filings MIRA

Mira Pharmaceuticals, Inc. has 198 filings in SEC EDGAR's recent list, going back to Jun 29, 2022. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (regulation fd disclosure).

Mira Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
424B5 Prospectus supplement Dec 5, 2025 —
424B5 Prospectus supplement Apr 16, 2025 —
424B5 Prospectus supplement Sep 27, 2024 —
S-8 Employee stock plan registration Sep 27, 2024 —
S-3 Shelf registration Aug 12, 2024 —
S-1 Registration statement Dec 18, 2023 —
424B3 Prospectus Nov 14, 2023 —
424B3 Prospectus Sep 18, 2023 —
424B4 Prospectus Aug 4, 2023 —
424B1 Filing Aug 4, 2023 —
S-1/A Amended registration statement Jul 28, 2023 —
S-1/A Amended registration statement Jul 25, 2023 —
S-1/A Amended registration statement Jul 21, 2023 —
S-1/A Amended registration statement Jul 18, 2023 —
S-1/A Amended registration statement Jul 14, 2023 —
S-1 Registration statement Jun 29, 2023 —

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MIRA (Nasdaq)
Incorporated in
FL
Headquarters
Miami, FL
SEC filer status
, Emerging growth company
SEC CIK
1904286
Former names
Mira1a Therapeutics, Inc. (until May 2, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.